← Search & browse all drugs
CARDIOVASCULAR SYSTEM › CARDIAC THERAPY › CARDIAC GLYCOSIDES › Other cardiac glycosides
peruvoside
C01AX02
Forms & Strengths
- Oral tablets: 0.25 mg
- Injectable solution: 0.1 mg/mL
Adult Dosing
- Digitalization (Rapid): 0.5 mg to 0.75 mg initially, followed by 0.25 mg every 4 to 6 hours as needed.
- Maintenance: 0.125 mg to 0.25 mg orally once daily.
Pediatric Dosing
- Safety and efficacy not established in pediatric patients; generally avoided.
Indications
- Congestive heart failure
- Supraventricular arrhythmias (e.g., atrial fibrillation, atrial flutter)
Mechanism of Action
- Inhibits myocardial Na+/K+-ATPase membrane pump, leading to increased intracellular sodium and subsequent elevation of intracellular calcium via the Na+/Ca2+ exchanger, resulting in positive inotropy.
Contraindications
- Digitalis-induced toxicity
- Ventricular fibrillation
- Second- or third-degree atrioventricular block without a pacemaker
- Hypertrophic obstructive cardiomyopathy
- Hypersensitivity to peruvoside or other cardiac glycosides
Adverse Reactions
- Cardiac arrhythmias (bradycardia, premature ventricular contractions, heart block)
- Nausea, vomiting, anorexia
- Visual disturbances (blurred vision, xanthopsia)
- Dizziness, fatigue, confusion
Drug Interactions
- Quinidine, verapamil, and amiodarone increase plasma concentrations of cardiac glycosides.
- Diuretics causing hypokalemia or hypomagnesemia significantly increase the risk of digitalis toxicity.
- Sympathomimetics and calcium salts increase the risk of cardiac arrhythmias.
Curated Content: Needs Vetting Before Put to Clinical Use